HIV-related outcomes may be affected by biological sex and by pregnancy. Including women in general and pregnant women in particular in HIV-related research is important for generalizability of findings.
To characterize representation of pregnant and non-pregnant women in HIV-related research conducted in general populations.
All HIV-related articles published in fifteen journals from January to March of 2011. We selected the top five journals by 2010 impact factor, in internal medicine, infectious diseases, and HIV/AIDS.
Study Eligibility Criteria
HIV-related studies reporting original research on questions applicable to both men and women of reproductive age were considered; studies were excluded if they did not include individual-level patient data.
Study appraisal and synthesis methods.
Articles were doubly reviewed and abstracted; discrepancies were resolved through consensus. We recorded proportion of female study participants, whether pregnant women were included or excluded, and other key factors.
In total, 2014 articles were published during this period. After screening, 259 articles were included as original HIV-related research reporting individual-level data; of these, 226 were determined to be articles relevant to both men and women of reproductive age. In these articles, women were adequately represented within geographic region. The vast majority of published articles, 183/226 (81%), did not mention pregnancy (or related issues); still fewer included pregnant women (n=33), reported numbers of pregnant women (n=19), or analyzed using pregnancy status (n=9).
Data were missing for some key variables, including pregnancy. The time period over which published works were evaluated was relatively short.
Conclusions and implications of key findings.
The under-reporting and inattention to pregnancy in the HIV literature may reduce policy-makers’ ability to set evidence-based policy around HIV/AIDS care for pregnant women and women of child-bearing age.
Citation: Westreich D, Rosenberg M, Schwartz S, Swamy G (2013) Representation of Women and Pregnant Women in HIV Research: A Limited Systematic Review. PLoS ONE 8(8): e73398. doi:10.1371/journal.pone.0073398
Editor: Rupert Kaul, University of Toronto, Canada
Received: February 1, 2013; Accepted: July 19, 2013; Published: August 23, 2013
Copyright: © 2013 Westreich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Institutes of Health in a grant from the Eunice Kennedy Shriver NICHD R00-HD-06-3961 and NIAID P30-AI-064518 to the Duke Center for AIDS Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Worldwide, about half of those living with HIV and AIDS are women and the majority of those women are of child-bearing age. In sub-Saharan Africa, where the HIV disease burden is most severe, more than 60% of adults living with HIV are women , and risk of HIV acquisition is concentrated among women of reproductive age. In South Africa, in particular, young women have more than three times the estimated prevalence of HIV infection compared with young men [2,3]. Prevalence of HIV is even higher among young women in antenatal care , and pregnancy is common among both HIV-infected women [4–7] and women at risk of HIV infection [4,8] throughout sub-Saharan Africa.
A substantial amount of HIV research to date has concentrated on prevention of mother to child transmission (PMTCT), as well as on the impact of PMTCT on subsequent maternal responses to highly active antiretroviral therapy (HAART) [9–12]. However, such research typically concentrates on pregnant women exclusively with primary outcomes that are not focused on maternal health but rather infant or child outcomes. Far less research is performed treating pregnancy either as an exposure (comparing pregnant to non-pregnant women) or as a confounder, modifier, or mediator of main effects .
Including pregnant women in non-pregnancy specific studies and assessing pregnancy as an exposure is important as pregnancy may influence HIV-related outcomes through hormonal, immunological or other physiological changes to the female body, or by altering drug pharmacokinetics [14,15]. Research around the impact of pregnancy on HIV progression and survival has produced varied findings [16–18]. Other studies have suggested that women are more susceptible to HIV-infection during pregnancy, as well as more likely to transmit HIV to partners [19,20]. Although evidence in these areas is limited and inconsistent , these examples reinforce the idea that pregnancy may impact HIV-related outcomes and should be considered when conducting HIV-related research.
To be relevant, HIV/AIDS research as a whole should be performed in populations with proportional composition to those affected by the disease. While all NIH-funded clinical trials were required to include women starting in 1993 with the NIH Revitalization Act (PL 103-43) , concerns remain about the representation of women in trials generally [23–26]. No such requirements apply to pregnant women, who have been routinely excluded from medical research in general and clinical trials in particular . No requirements exist for the inclusion of either women or pregnant women in observational research, nor do related guidelines such as STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) mention this issue .
It is at present unknown if women are adequately represented in HIV/AIDS research, in either observational or experimental studies. Informally, we have observed that HIV/AIDS research within general populations typically fails to meaningfully address pregnancy, either by excluding pregnant women where no such exclusion is justifiable, or by failing to address pregnancy in a population which includes numerous women of reproductive age. Such exclusions, if widespread, may lead to biased research findings. Here, we sought to formalize these perceptions by assessing the frequency with which pregnant women, and women in general, are included or excluded from representative publications in the peer-reviewed HIV/AIDS literature dealing with research conducted in general populations – that is, in studies dealing with questions relevant to both men and women generally.
Materials and Methods
Types of studies and search strategy
To quantify how well women and pregnant women were represented among representative current studies of HIV, we examined all HIV-related articles officially published between January and March 2011 from fifteen high impact journals which publish HIV/AIDS research. Using the Journal Citation Report (Science) , we identified the top five journals publishing primarily original research by 2010 impact factor within each of three categories: general and internal medicine; infectious diseases; and HIV/AIDS. The first group of journals comprised the top five journals listed by impact factor in the journal category “Medicine, General & Internal”; the latter two groups of journals were both drawn from the category “Infectious Diseases”. The AIDS-specific journals were the top five journals by impact factor in this category with “HIV” or “AIDS” in the journal title; the infectious diseases journals were the top five journals by impact factor in the category after removal of the AIDS-specific journals. As our goal was to assess the mainstream AIDS literature and research relevant to the general population, we deliberately did not consider journals focused on obstetrics and gynecology or women’s health.
We conducted the search within these fifteen journals over a publication period of three months using PubMed.gov and the journal websites. We restricted the search to remove common publication types which do not include original research: historical articles, news, editorials, non-research-letters, comments, reviews, meta-analyses, case reports, and patient education handouts (accounting for slight variations in naming conventions among journals). We restricted further to the studies related to HIV using the following search terms: “HIV”, “AIDS”, “retrovir*”, and “human immunodeficiency virus” (where * indicates a match to any text string, so “retrovir*” will match, among other things, “antiretroviral”).
All articles identified by the above search criteria were considered. Articles were independently and doubly reviewed and abstracted; discrepancies in abstracted data were resolved through consensus. Articles were removed from further analysis if they were unrelated to HIV (e.g., involving an alternative retrovirus); not original research (e.g., commentaries or invited reviews); or ecological, modeling, surveillance, or other studies which did not report or analyze individual-level data. If articles referred to a previously defined study population (e.g., an observational study performed within a randomized trial population), the original referenced description of the population was identified and used to abstract additional information if necessary. The remaining studies were then screened for those with research questions relevant to pregnant women only, primarily children under 11, or men only. Studies which addressed a research question which was not male-specific, but which was done in an all-male population, were not considered as research questions relevant to men only.
Data collection and analysis
Among studies with research questions potentially relevant to men and women of reproductive age, we abstracted data on the participation and analysis of women and pregnant women in the study and article. Specifically, we recorded: the proportion of study participants who were women; whether pregnant women were included or excluded, or if no data were collected on pregnancy status; and whether or not the article mentioned pregnancy at all (using search strings: “preg”, “matern”, “grav”, “natal”, and “child”). For articles which did not report proportion women or inclusion/exclusion criteria involving pregnancy, we contacted authors by email to ascertain this information. Additional characteristics abstracted from the articles included: observational versus experimental study type, whether or not the study used a previously defined study population, country and region in which the study was performed, sample size, and age range of participants.
To contextualize the inclusion of women in research, we searched UNAIDS, CDC, and US Government websites to obtain estimates of the proportion female among persons living with HIV and AIDS in each major world region. We compared these estimates to the proportion of female study subjects included in the reviewed manuscripts by region (calculated as total female participants within all studies in the same region divided by total participants from all studies in that region). To explore the possibility that representation of women and pregnant women may differ by type of research, we examined the participation of women and pregnant women stratified by whether the study was experimental or observational.
Two main analyses were conducted using simple descriptive statistics: first, the representation of women in studies. Second, the inclusion or exclusion of pregnant women in studies.
Table 1 lists the fifteen journals identified for review. Of 2,014 total articles published in the identified journals from January to March 2011, a total of 318 articles contained HIV-related keywords. Of these 318 studies, 59 were removed because they contained no individual-level demographic data (n=18), they were not original research (n=17), or for other reasons (n=24), listed in Figure 1. Of the 259 remaining HIV-related articles, 19 addressed a pregnancy-specific research question; 7 addressed a male-specific research question; and 7 included a study population of all (or large majority) children under age 11. We judged that the remaining 226 articles could have included men and both pregnant and non-pregnant women. These 226 studies comprise our data set for subsequent analyses and are listed in appendix File S1. These studies were assessed by region: 152 (67%) studies were from North America, Western or Central Europe, while 32 (14%) were from sub-Saharan Africa.
|Subject||Title||Total Articles||Research Articles||HIV/AIDS Articles|
|General Medicine||The New England Journal of Medicine||340||112||1|
|JAMA: The Journal of the American Medical Association||235||89||4|
|Annals of Internal Medicine||148||42||0|
|Infectious Disease||The Lancet Infectious Diseases||51||13||3|
|Clinical Infectious Diseases||193||105||29|
|Emerging Infectious Diseases||137||73||3|
|Journal of Infectious Diseases||125||100||30|
|Clinical Microbial Infections||82||61||3|
|JAIDS: Journal of Acquired Immune Deficiency Syndromes||79||60||60|
|AIDS Patient Care||32||21||21|
|AIDS Research Human Retroviruses||46||39||38|
Figure 1. Flowchart of included studies.
1Historical articles, news, editorials, letters, comments, case reports, reviews, patient education handouts, meta-analyses. 2Keywords: HIV, AIDS, anti-retrovir*, antiretrovir*, retrovir*, human immunodeficiency virus. 3Ecological studies, surveillance studies, animal studies, modeling studies. 4Commentary, reviews, invited articles. 5Other retroviruses, studies of non-HIV related outcomes in HIV-negative populations, study of clinicians/service providers, studies in non-human subjects, blood donation screening study.doi:10.1371/journal.pone.0073398.g001
Representation of women
Of the 226 evaluable studies, 196 had complete sample size and percentage female available for analysis. In these 196 studies, women were generally represented at or above the estimated within-region normative values (Table 2). Exceptions were the Caribbean, where we evaluated only a single study involving 7 people, and Asia/Pacific, where representation of women was slightly below normative levels. We note that these by-region normative values may in fact understate the expected percentage female among women of reproductive age, because in many settings (including sub-Saharan Africa) young women are at higher risk of HIV infection than young men.
|Regional information:||Among studies analyzed:|
|Region||% female among PLWHA‡||% pregnant among PLWHA†||# studies||# analyzed||# subjects||% subjects female|
Despite the fact that women were represented adequately within region, they were underrepresented overall: while 50% of people living with HIV and AIDS worldwide are women, only 38.5% of those in these studies were woman. This is due primarily to the large proportion of studies and study subjects (73%) from North America and Europe, where women are underrepresented compared to the total world population of people living with HIV and AIDS (although women were overrepresented in studies from this region, see Table 2). Of the 226 studies relevant to men and women, 11 (5%) included no women at all, while 9 (4%) included only women.
Representation of pregnancy and pregnant women
Only 43 (19%) mentioned pregnancy at any point in the article, while 81% did not mention pregnancy (Table 3). A total of 33 studies (15%) included pregnant women in the study population, while 104 (46%) included no pregnant women. In 89 studies (39%), it was unknown whether pregnant women were included in their analysis, because no information was present in the manuscript and either authors stated by email that they did not know whether pregnant women were included in their analysis (34 studies), or authors did not respond to email (55 studies).
|Characteristics||Total n=226||By study design:||Among observational studies only:|
|Experimental n=25||Observational n=151||Previous cohort n=104||Original cohort n=47|
|Included no women||11 (5%)||4 (16%)||6 (4%)||4 (4%)||2 (4%)|
|Pregnancy not mentioned||183 (81%)||17 (68%)||122 (81%)||84 (81%)||38 (81%)|
|Inclusion||33 (15%)||2 (8%)||26 (17%)||22 (21%)||4 (9%)|
|Non-inclusion||104 (46%)||20 (80%)||67 (44%)||45 (43%)||22 (47%)|
|Exclusions‡||61 (27%)||16 (64%)||39 (26%)||31 (30%)||8 (17%)|
|Unknown||89 (39%)||3 (12%)||58 (38%)||37 (36%)||21 (45%)|
Of the 104 studies which did not include pregnant women, 25 (including 7 trials) explicitly excluded pregnant (and/or recently pregnant, or lactating women). There were a variety of reasons (explicit and implicit) for these exclusions (although some studies gave no reasons, e.g. [30–32]). Some studies noted differences in: management of pregnant women : study sites at which pregnant women are seen ; or the potential for pregnancy related physiologic changes relevant to study aims . Numerous studies [36–40] examined questions related to efavirenz, a possible reason for the exclusion of pregnant women, though few if any of these studies were explicit about reasons for the exclusion. Six (related) observational studies of current users of buprenorphine [41–46] excluded pregnant women. Three studies which excluded pregnancy were H1N1 vaccine studies [47–49]; one identified pregnant women as being at particularly high risk from H1N1 before then excluding pregnant women .
Another 36 studies implicitly excluded pregnant women. Implicit exclusions took several forms. Among these were studies which performed secondary analysis of data from a trial which had, itself, excluded pregnant women; studies which mentioned pregnancy exclusions on the trial registration website, but not in the paper; studies which used an all-male cohort or analysis to answer a research question which was not male-specific; or studies for which exclusions were only communicated by email, not in the paper. Two studies [50,51] examined an outcome of incident pregnancy but excluded prevalent pregnancies; we did not count these two studies as excluding pregnant women.
Of the 33 studies which did include pregnant women as part of their study population, 16 did not mention this in their text; the information was obtained by author query. A total of 12 studies out of the 226 assessed (7%) reported the actual number of incident and/or prevalent pregnancies in the article text; another 7 studies reported the number of pregnancies via author correspondence. Only 9 studies used pregnancy status in analysis: as a covariate (n=3), an outcome (n=2), subgroup (n=2), exposure (n=1), or describing distribution of pregnancy status between arms of a trial (n=1).
Experimental vs. observational studies
We then limited our 226 studies to 176 population-based experimental and observational studies, excluding laboratory, genetic, diagnostic testing studies, and ambiguous study designs; there were 25 experimental studies and 151 observational studies. In this subset, women continued to be represented adequately in both experimental and observational studies when considered by region.
Experimental studies were somewhat more likely to mention pregnancy (8/25 experimental vs. 29/151 observational, χ2 p=0.15), but less likely to include pregnant women (2/25 vs. 27/151, χ2 p=0.22); neither result was statistically significant. Experimental studies were more likely to exclude pregnancy (all exclusions: 16/25 experimental vs. 39/151 observational, χ2 p<0.001). In studies where pregnancy was mentioned, experimental studies were more likely to exclude pregnancy as well (7/8 vs. 15/29; χ2 p=0.068).
Original observational cohort studies
Among the 151 observational studies noted above, only 47 were performed in original cohorts, rather than being nested in other studies or trials. Of these, 9 (19%) mentioned pregnancy; 4 (9%) included pregnant women; and 8 (17%) excluded pregnant women explicitly or implicitly.
Women comprise 50% of those living with HIV and AIDS throughout the world, and women of reproductive age are at highest risk of HIV infection among those women. In Sub-Saharan African, where the heterosexual epidemic is most heavily concentrated, pregnancy is common among HIV-positive women, especially after the initiation of HAART [4–7]. In this systematic review of a sample of high impact HIV-related scientific literature, we found that women appear to be adequately represented in HIV/AIDS research conducted in the general population. Of concern, however, we also found that pregnant women are underrepresented in studied populations and that the great majority of HIV literature does not consider the presence or impact of pregnancy in their populations.
While a relatively low percentage of people living with HIV and AIDS are pregnant at a given time (Table 2), over time a large percentage of HIV-positive women are likely to experience pregnancy [4,50,52]. Given the importance of pregnancy, we would argue that more papers should be at least commenting on pregnancy in their cohort. Not only did 81% of papers not even mention pregnancy (or related terms) in their papers, we found from email correspondence that many investigators had no idea how many – indeed, if any – pregnant women were included in their study. UNAIDS has said that researchers “should recruit women… including those who may become pregnant, be pregnant or be breastfeeding” into clinical trials, since those women should be the “recipients of future safe and effective biomedical HIV prevention interventions.” [27,53] This has not yet come to pass: tellingly, the CONSORT website’s example on how to describe eligibility criteria for a trial is of an HIV trial which excludes pregnant women [54,55]. An even stronger case can be made for the inclusion of pregnant women in observational studies, which – unlike many trials – rarely introduce interventions such as new pharmacological agents which may pose fetal risks. Indeed, the fact that many RCTs systematically exclude pregnant women, often for good reason , means that it is even more important for observational studies to collect data from this group in order to better understand the safety of drugs, interventions, and outcomes for women exposed to pregnancy. Thus, we hoped to see better inclusion of pregnant women in observational studies than in experimental studies; inclusion was indeed higher in observational studies but remained low overall at 17%.
Many observational studies are themselves nested within “parent” cohorts or populations, a set of studies of which 21% included pregnant women. This puts the question of pregnancy out of the hands of investigators, especially when the parent cohort is a trial population and thus may well exclude pregnancy by design. While the use of existing data is tempting, we would urge future investigators to consider more carefully whether those data have exclusion criteria which make them inappropriate for the study question at hand. We would also urge investigators to do a more complete job of explaining the specific exclusion criteria in the parent study, and to specify the impact of these criteria on the generalizability of study findings.
Among original (non-nested) observational studies, only 9% included pregnant women: thus, there is a clear need for closer attention to pregnancy-related issues among researchers building new cohorts. Some of these studies were open to both non-pregnant and pregnant women, but enrolled only males and/or non-pregnant women. Thus, care must be taken in the design and recruitment stage to ensure adequate participant recruitment at appropriate levels for important subgroups.
Although women were underrepresented in the reviewed manuscripts, comprising less than 40% of the total subjects in these studies, women were adequately represented within region, e.g., the proportion of women subjects in studies from sub-Saharan Africa exceeded the estimated underlying proportion of women living with HIV and AIDS in that region. These apparently contradictory findings are due to the overrepresentation of the US/Europe among studies (152/226, 67%) and subjects (73% of total participants). In contrast, only 14% of the studies and 12% of subjects were from sub-Saharan Africa, where approximately two-thirds of all HIV-positive individuals reside.
There were limitations of this work. The review was conducted over a relatively short time period (three months, January through March 2011) and a set of fifteen journals which, while high impact and relevant to the HIV field, may not perfectly represent all population-based HIV research. It is possible that publications in lower-impact journals are including pregnant women in higher numbers. However, pregnancy is a significant and common issue among HIV-infected women and therefore a “high-impact” concern; the absence of pregnancy from high-impact publications is therefore problematic regardless of representation elsewhere. Laboratory-based studies were often hard to abstract data from because they frequently lack demographic data: however, we would argue that it would enhance reports of laboratory work to report basic demographics, including age, gender, and pregnancy status of the samples along with laboratory findings. Finally, there were substantial missing data for some variables, e.g., 39% of the 226 studies had no information available regarding pregnancy (Table 3). However, it seems clear that if pregnant women were not enumerated in results or mentioned in an article at all, that pregnancy was not being considered in the analysis, and that pregnancy data are not reaching the audience who make decisions about HIV/AIDS care for pregnant women and women of child-bearing age.
There are numerous challenges to including pregnancy in observational and well as experimental research, among them the time-varying nature of pregnancy, potential costs of laboratory testing, potential misreporting of pregnancy, and additional human subjects protections for the inclusion of pregnant women in research. Nonetheless, evidence-based public health policy necessitates research within those populations to which interventions will be targeted. In their guidance document, “Ethical considerations in biomedical HIV prevention trials”, UNAIDS/WHO states:
Researchers and trial sponsors should recruit women into clinical trials in order to verify safety and efficacy from their standpoint… since women throughout the life span, including those who may become pregnant, be pregnant or be breastfeeding, should be recipients of future safe and effective biomedical HIV prevention interventions .
It is clear that this statement applies to observational as well as experimental research efforts. In particular, observational studies can and should specifically assess the impact of interventions in populations that have been previously excluded from trial research, in order to better understand the generalizability of findings. Current HIV research in general populations, both experimental and observational, appears to adequately represent women in general, but appears to be insufficiently including, reporting, and analyzing pregnant women. This is both an ethical, and a scientific, issue.
Bibliography of 226 studies considered in Table 2.
Conceived and designed the experiments: DW MR GS. Performed the experiments: DW MR SS. Analyzed the data: DW. Contributed reagents/materials/analysis tools: DW MR SS. Wrote the manuscript: DW MR SS GS. Originated the paper, framed questions and review strategy, oversaw literature review conducted by MR and SS, conducted some literature review and data abstraction, led writing of paper: DW. Had full access to all the data in the study and has final responsibility for the decision to submit for publication: DW. Helped frame the questions and review strategy, conducted the literature review, abstracted data, helped write and edit the paper, and created figures: MR SS. Helped frame the questions and review strategy, and helped write and edit the paper: GS.
- 1. UNAIDS (2008) 2008 Report on the global AIDS epidemic. Available: . http://wwwunaidsorg/en/KnowledgeCentre/HIVData/GlobalReport/2008 /. Geneva.
- 2. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C et al. (2005) Young people’s sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19: 1525-1534. doi:10.1097/01.aids.0000183129.16830.06. PubMed: 16135907.
- 3. UNAIDS/WHO (2007). ids Epidemic Update: 2007. Geneva.
- 4. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM et al. (2010) Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLOS Med 7: e1000229. PubMed: 20161723.
- 5. Schwartz S, Mehta S, Taha T, Rees H, Venter F et al. (2011) High Pregnancy Intentions and Missed Opportunities for Patient-Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy. AIDS Behav.
- 6. Westreich D, Maskew M, Rubel D, MacDonald P, Jaffray I et al. (2012) Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis. In press at Infectious Diseases in Obstetrics & Gynecology.. PubMed: 22778536.
- 7. Schwartz SR, Rees H, Mehta S, Venter WD, Taha TE et al. (2012) High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLOS ONE 7: e36039. doi:10.1371/journal.pone.0036039. PubMed: 22558319.
- 8. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M et al. (2011) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40: 922-930. doi:10.1093/ije/dyq176. PubMed: 21047913.
- 9. Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V et al. (2007) Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21: 957-964. doi:10.1097/QAD.0b013e32810996b2. PubMed: 17457089.
- 10. Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB et al. (2008) Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 46: 611-621. doi:10.1086/526780. PubMed: 18197758.
- 11. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, et al (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229-240. doi:10.1056/NEJMoa041305. PubMed: 15247339.
- 12. Westreich D, Eron J, Behets F, Horst Cv, Van Rie A (2007) Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 195: 837-846. doi:10.1086/511276. PubMed: 17299714.
- 13. MacCarthy S, Laher F, Nduna M, Farlane L (2009) Responding to Her Question: A Review of the Influence of Pregnancy on HIV Disease Progression in the Context of Expanded Access to HAART in Sub-Saharan Africa. AIDS Behav, 13 Suppl 1: 66–71. PubMed: 19301115.
- 14. van Hasselt JG, Andrew MA, Hebert MF, Tarning J, Vicini P et al. (2012) The Status of Pharmacometrics in Pregnancy: Highlights from the 3(rd) American Conference on Pharmacometrics. Br J Clin Pharmacol, 74: 932–9. PubMed: 22452385.
- 15. Mirochnick M, Capparelli E (2004) Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43: 1071-1087. doi:10.2165/00003088-200443150-00002. PubMed: 15568888.
- 16. Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C et al. (2011) Pregnancy and virologic response to antiretroviral therapy in South Africa. PLOS ONE 6: e22778. doi:10.1371/journal.pone.0022778. PubMed: 21829650.
- 17. French R, Brocklehurst P (1998) The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105: 827-835. doi:10.1111/j.1471-0528.1998.tb10226.x. PubMed: 9746374.
- 18. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF et al. (2007) Pregnancy and HIV Disease Progression during the Era of Highly Active Antiretroviral Therapy. J Infect Dis 196: 1044-1052. doi:10.1086/520814. PubMed: 17763327.
- 19. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H et al. (2005) Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366: 1182-1188. doi:10.1016/S0140-6736(05)67481-8. PubMed: 16198767.
- 20. Mugo NR, Heffron R, Donnell D, Wald A, Were EO et al. (2011) Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 25: 1887-1895. doi:10.1097/QAD.0b013e32834a9338. PubMed: 21785321.
- 21. Morrison CS, Wang J, Van Der Pol B, Padian N, Salata RA et al. (2007) Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS 21: 1027-1034. doi:10.1097/QAD.0b013e3280f00fc4. PubMed: 17457097.
- 22. National Institutes of Health (2001) NIH Policy and Guidelines on the inclusion of women and minorities as subjects in Clinical Research – Amended, October (2001). MD: Bethesda.
- 23. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED (2001) Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286: 708-713. doi:10.1001/jama.286.6.708. PubMed: 11495621.
- 24. Foulkes MA (2011) After inclusion, information and inference: reporting on clinical trials results after 15 years of monitoring inclusion of women. J Womens Health (Larchmt) 20: 829-836. doi:10.1089/jwh.2010.2527.
- 25. Weinberger AH, McKee SA, Mazure CM (2010) Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health (Larchmt) 19: 1727-1732. doi:10.1089/jwh.2009.1784. PubMed: 20799923.
- 26. Berlin JA, Ellenberg SS (2009) Inclusion of women in clinical trials. BMC Med 7: 56. doi:10.1186/1741-7015-7-56. PubMed: 19818115.
- 27. Macklin R (2010) Enrolling pregnant women in biomedical research. Lancet 375: 632-633. doi:10.1016/S0140-6736(10)60257-7. PubMed: 20198725.
- 28. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18: 800-804. doi:10.1097/EDE.0b013e3181577654. PubMed: 18049194.
- 29. ISI (2010) Web of Knowledge. J Citation Rep Science. (Accessed April 30 2012). . Thomson: Reuters , New York.
- 30. Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Bärnighausen T (2011) Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDs 25: 163-170. PubMed: 21269131.
- 31. da Silva GK, Guimarães R, Mattevi VS, Lazzaretti RK, Sprinz E et al. (2011) The role of mannose-binding lectin gene polymorphisms in susceptibility to HIV-1 infection in Southern Brazilian patients. AIDS 25: 411-418. doi:10.1097/QAD.0b013e328342fef1. PubMed: 21192229.
- 32. Finocchario-Kessler S, Catley D, Berkley-Patton J, Gerkovich M, Williams K et al. (2011) Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: the role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDs 25: 103-111. doi:10.1089/apc.2010.0319. PubMed: 21235403.
- 33. Yi T, Cocohoba J, Cohen M, Anastos K, DeHovitz JA et al. (2011) The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr 56: 253-262. doi:10.1097/QAI.0b013e31820a9d04. PubMed: 21239994.
- 34. Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K et al. (2011) Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med 12: 46-53. doi:10.1111/j.1468-1293.2010.00850.x. PubMed: 20553336.
- 35. Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE et al. (2011) Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retrovir 27: 35-39. doi:10.1089/aid.2010.0129. PubMed: 20929397.
- 36. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovirdisoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25: F7-12. doi:10.1097/QAD.0b013e328345766f. PubMed: 21412057.
- 37. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 12: 157-165. doi:10.1111/j.1468-1293.2010.00864.x. PubMed: 20722752.
- 38. Lartey M, Sagoe KW, Yang H, Kenu E, Xexemeku F et al. (2011) Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. Clin Infect Dis 52: 547-550. doi:10.1093/cid/ciq196. PubMed: 21252140.
- 39. Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M et al. (2011) A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 25: 57-63. doi:10.1097/QAD.0b013e32833f9f63. PubMed: 21076278.
- 40. Waters L, Fisher M, Winston A, Higgs C, Hadley W et al. (2011) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25: 65-71. doi:10.1097/QAD.0b013e328341685b. PubMed: 21099666.
- 41. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT et al. (2011) HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 56 Suppl 1: S22-S32. doi:10.1097/QAI.0b013e318209751e. PubMed: 21317590.
- 42. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL et al. (2011) Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 56 Suppl 1: S33-S38. doi:10.1097/QAI.0b013e3181fcbcb4. PubMed: 21317592.
- 43. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL et al. (2011) Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr 56 Suppl 1: S83-S90. doi:10.1097/01.qai.0000397379.23943.e1. PubMed: 21317600.
- 44. Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L et al. (2011) Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 56 Suppl 1: S39-S45. doi:10.1097/QAI.0b013e3182055138. PubMed: 21317593.
- 45. Sullivan LE, Botsko M, Cunningham CO, O’Connor PG, Hersh D et al. (2011) The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 56 Suppl 1: S54-S61. doi:10.1097/01.qai.0000397320.40083.fa. PubMed: 21317595.
- 46. Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F et al. (2011) Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 56 Suppl 1: S62-S67. doi:10.1097/01.qai.0000397336.79987.d8. PubMed: 21317596.
- 47. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A et al. (2011) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 52: 138-146. doi:10.1093/cid/ciq056. PubMed: 21148532.
- 48. Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A et al. (2011) Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25: 177-183. doi:10.1097/QAD.0b013e328341afa8. PubMed: 21150561.
- 49. Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D et al. (2011) Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 52: 248-256. doi:10.1093/cid/ciq104. PubMed: 21288852.
- 50. Linas BS, Minkoff H, Cohen MH, Karim R, Cohan D et al. (2011) Relative time to pregnancy among HIV-infected and uninfected women in the Women’s Interagency HIV Study, 2002-2009. AIDS 25: 707-711. doi:10.1097/QAD.0b013e3283445811. PubMed: 21297418.
- 51. Agwu AL, Jang SS, Korthuis PT, Araneta MR, Gebo KA (2011) Pregnancy incidence and outcomes in vertically and behaviorally HIV-infected youth. JAMA 305: 468-470. doi:10.1001/jama.2011.79. PubMed: 21285423.
- 52. Westreich D, Maskew M, Rubel D, Macdonald P, Jaffray I et al. (2012) Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis. Infect Dis Obstet Gynecol, 2012: 2012: 917059. PubMed: 22778536.
- 53. UNAIDS/WHO (2007) Ethical considerations for biomedical HIV prevention trials: guidance document. Available: http://data.unaids.org/pub/manual/2007/jc1349_ethics_2_11_07_en.pdf. Accessed 2 August 2013.
- 54. CONSORT (2007). tem: 4a Eligibility criteria for participants. Geneva.
- 55. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H et al. (2009) Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 338: b1867. doi:10.1136/bmj.b1867. PubMed: 19465470.
- 56. CDC (2012) HIV in the United States: At A Glance. Available: http://www.cdc.gov/hiv/resources/factsheets/us.htm.
- 57. UNAIDS (2012) Women, girls, gender equality and HIV. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2012/20120217_FS_WomenGirls_en.pdf.
- 58. WomensHealth.gov (2011) AIDS worldwide. http://www.womenshealth.gov/hiv-aids/aids-worldwide/.
- 59. UNAIDS (2010) Mother-to-child transmission of HIV data and statistics. Available: http://www.who.int/hiv/topics/mtct/data/en/index1.html.
- 60. UNAIDS (2012) Global Fact Sheet, World AIDS Day 2012. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_FactSheet_Global_en.pdf.